A detailed history of Pacer Advisors, Inc. transactions in Bio N Tech Se stock. As of the latest transaction made, Pacer Advisors, Inc. holds 1,103 shares of BNTX stock, worth $86,872. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,103
Previous 1,131 2.48%
Holding current value
$86,872
Previous $119,000 15.13%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$88.96 - $112.35 $2,490 - $3,145
-28 Reduced 2.48%
1,103 $101,000
Q4 2023

Jan 16, 2024

SELL
$90.91 - $112.75 $2,090 - $2,593
-23 Reduced 1.99%
1,131 $119,000
Q3 2023

Nov 13, 2023

BUY
$98.5 - $125.08 $4,137 - $5,253
42 Added 3.78%
1,154 $125,000
Q2 2023

Jul 12, 2023

BUY
$102.58 - $129.66 $8,411 - $10,632
82 Added 7.96%
1,112 $120,000
Q1 2023

May 02, 2023

BUY
$122.57 - $153.67 $2,573 - $3,227
21 Added 2.08%
1,030 $128,000
Q4 2022

Feb 06, 2023

BUY
$118.43 - $186.05 $74,018 - $116,281
625 Added 162.76%
1,009 $151,000
Q3 2022

Oct 18, 2022

SELL
$127.65 - $183.11 $16,211 - $23,254
-127 Reduced 24.85%
384 $52,000
Q2 2022

Aug 12, 2022

BUY
$123.25 - $186.24 $862 - $1,303
7 Added 1.39%
511 $76,000
Q1 2022

Apr 05, 2022

SELL
$126.25 - $231.85 $95,571 - $175,510
-757 Reduced 60.03%
504 $86,000
Q4 2021

Feb 03, 2022

BUY
$216.64 - $362.52 $72,357 - $121,081
334 Added 36.03%
1,261 $325,000
Q3 2021

Oct 15, 2021

BUY
$205.93 - $447.23 $121,292 - $263,418
589 Added 174.26%
927 $253,000
Q2 2021

Jul 21, 2021

BUY
$113.32 - $241.49 $38,302 - $81,623
338 New
338 $76,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $19.1B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Pacer Advisors, Inc. Portfolio

Follow Pacer Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.